Articles related to CHECKPOINT INHIBITORS

Discover how a novel combination therapy targeting EGFR and AXL proteins could revolutionize the treatment of head and neck squamous cell carcinoma and lung adenocarcinoma.

The recent phase 2 study on atezolizumab shows promising results in inducing sustained responses in advanced ASPS patients.

The FDA’s recent approval of Akeega, a combination therapy for BRCA-mutated mCRPC, marks a significant advancement in targeted treatment. This approval, based on the MAGNITUDE study, offers a new therapeutic option for patients, supported by robust clinical data.

Explore the complexities of treating small cell lung cancer (SCLC) after platinum-based therapy failure, including insights into immune checkpoint inhibitors, the preference for lurbinectedin, and the potential of liquid biopsies. Join Dr. Misty Shields in understanding the challenges and opportunities in this evolving field.

Explore the findings of the A041702 study, presented at the ASCO annual meeting, which investigated the efficacy of two treatment regimens for older patients with CLL. The results, significantly influenced by COVID-19, call for further investigation and long-term follow-up to determine the potential benefits and risks.

The landscape of small cell lung cancer treatment is undergoing significant transformation with the advent of immune checkpoint inhibitors. This shift not only provides new therapeutic options but emphasizes the importance of a comprehensive team approach, including early detection strategies, and holds the promise for enhanced patient prognosis.